FindTrial
Sign In

Randomized phase III trial of amrubicin vs. carboplatin plus etoposide in elderly patients with extensive-disease small-cell lung cancer

Randomized phase III trial of amrubicin vs. carboplatin plus etoposide in elderly patients with extensive-disease small-cell lung cancer

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1080220200
Enrollment
Unknown
Registered
2006-01-27
Start date
2006-01-27
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Extensive-disease small-cell lung cancer (ED-SCLC)

Interventions

investigational material(s) Generic name etc : SM-5887 (Amrubicin Hydrochloride) INN of investigational material : Therapeutic category code : 423 Antitumor antibiotics and preparations Dosage and Ad

Sponsors

Dainippon Sumitomo Pharma Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Extensive-disease small-cell lung cancer - Aged 70 years or elder - Performance status of 0-2 - No prior chemotherapy etc. - Prior therapy for primary lesion - Pneumonitis and/or pulmonary fibrosis - Active concomitant malignancy etc.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Efficacy: Overall survival etc—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026